Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Quentin M Anstee

Showing results (131-140 of 261) with videos related to

Pageof 27
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2016
Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled TrialDavid Houghton, Christian Thoma, Kate Hallsworth, et al.
Lasers in Surgery and Medicine|June 16, 2011
Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver diseaseVincent R Sauvage, Adam P Levene, Hoa T Nguyen, et al.
Journal of Clinical Medicine|July 2, 2021
Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver DiseaseAnne-Marieke Van Dijk, Yasaman Vali, Anne Linde Mak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2023
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized StudyQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Hepatology Communications|December 21, 2023
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 studyArun J Sanyal, Rohit Loomba, Quentin M Anstee, et al.
JHEP Reports : Innovation in Hepatology|March 11, 2024
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASHQuentin M Anstee, Jeremy Magnanensi, Yacine Hajji, et al.
JHEP Reports : Innovation in Hepatology|March 11, 2026
The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLDDina G Tiniakos, Pierre Bedossa, Johanna Arola, et al.
Gastroenterology|August 1, 2017
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver ForumYuval A Patel, Joanne C Imperial, Andrew J Muir, et al.
Plos One|July 5, 2013
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in miceMichelle Goldsworthy, Nathan L Absalom, David Schröter, et al.
Alimentary Pharmacology & Therapeutics|March 15, 2023
Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trialsJuan M Pericàs, Nicholas A Di Prospero, Quentin M Anstee, et al.
Pageof 27

Showing results (131-140 of 261) with videos related to

Sort By:
Pageof 27
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2016
Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled TrialDavid Houghton, Christian Thoma, Kate Hallsworth, et al.
Lasers in Surgery and Medicine|June 16, 2011
Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver diseaseVincent R Sauvage, Adam P Levene, Hoa T Nguyen, et al.
Journal of Clinical Medicine|July 2, 2021
Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver DiseaseAnne-Marieke Van Dijk, Yasaman Vali, Anne Linde Mak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2023
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized StudyQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Hepatology Communications|December 21, 2023
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 studyArun J Sanyal, Rohit Loomba, Quentin M Anstee, et al.
JHEP Reports : Innovation in Hepatology|March 11, 2024
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASHQuentin M Anstee, Jeremy Magnanensi, Yacine Hajji, et al.
JHEP Reports : Innovation in Hepatology|March 11, 2026
The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLDDina G Tiniakos, Pierre Bedossa, Johanna Arola, et al.
Gastroenterology|August 1, 2017
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver ForumYuval A Patel, Joanne C Imperial, Andrew J Muir, et al.
Plos One|July 5, 2013
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in miceMichelle Goldsworthy, Nathan L Absalom, David Schröter, et al.
Alimentary Pharmacology & Therapeutics|March 15, 2023
Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trialsJuan M Pericàs, Nicholas A Di Prospero, Quentin M Anstee, et al.
Pageof 27